No Data
No Data
Following Recent Decline, Yunkang Group Limited's (HKG:2325) Top Shareholder CEO Yong Zhang Sees Holdings Value Drop by 6.7%
Yunkang Group Schedules AGM, Proposes Dividend
YUNKANG GROUP: NOTICE OF ANNUAL GENERAL MEETING
YUNKANG GROUP: 2023 ANNUAL REPORT
China Post Securities: Endogenous growth is steady, and the Hong Kong stock healthcare services sector's valuation is highly attractive
Judging from the overall performance of medical service targets in Hong Kong stocks, with the exception of ICL's high revenue base in the early COVID-19 period, where dental revenue was affected by dental implant collection, most of the revenue from other medical service targets increased relatively well.
Read Yunkang Group (2325.HK)'s 2023 performance report in one picture
On March 25, Yunkang Group (2325.HK) announced its 2023 results announcement. In 2023, the company recorded revenue of 892 million yuan (RMB, same unit), an increase of 31.5% compared with 2019. As of December 31, 2023, Yunkang's customers spread across 31 provinces and autonomous regions, and more than 200 cities. It has built 416 medical consortium on-site diagnosis centers, 1,500+ medical and non-medical institutions, 3,900 medical and non-medical institutions, with more than 3,000 testing projects, and the company has more than 800 doctors and medical technicians. underneath
No Data